Functional overexpression and purification of a codon optimized synthetic glucarpidase (carboxypeptidase G2) in Escherichia coli
- PMID: 19911261
- DOI: 10.1007/s10930-009-9211-2
Functional overexpression and purification of a codon optimized synthetic glucarpidase (carboxypeptidase G2) in Escherichia coli
Abstract
Glucarpidase (former name: carboxypeptidase G2, or CPG2) is a bacterial enzyme that is widely used in detoxification of the cytotoxic drug, methotrexate, and in Antibody Directed Enzyme Prodrug Therapy for cancer treatment. The glucarpidase gene of Pseudomonas sp. strain RS-16 was previously cloned in E coli, but expresses at a level that is approximately 100-fold lower than in the native strain. In this study, a synthetic gene coding for glucarpidase was codon-optimised and synthesized for maximum expression in E. coli using the vector pET28a. Our work indicated that the enzyme was expressed to ~60% of the total host protein and that purification of the recombinant His-tagged protein could be achieved in a single step by Ni(2+) charged column chromatography. The synthetic recombinant glucarpidase expressed within this system was biologically active and zinc dependant. Our study showed that Mg(2+) as well as Mn(2+) ions inhibit the activity of the recombinant enzyme.
Similar articles
-
Characterization of a Stable Form of Carboxypeptidase G2 (Glucarpidase), a Potential Biobetter Variant, From Acinetobacter sp. 263903-1.Mol Biotechnol. 2021 Dec;63(12):1155-1168. doi: 10.1007/s12033-021-00370-3. Epub 2021 Jul 15. Mol Biotechnol. 2021. PMID: 34268672
-
Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.Biomed Pharmacother. 2019 Apr;112:108725. doi: 10.1016/j.biopha.2019.108725. Epub 2019 Feb 28. Biomed Pharmacother. 2019. PMID: 30970523
-
Enhanced Solubility and One-Step Purification of Functional Dimeric Carboxypeptidase G2.Biochemistry (Mosc). 2021 Feb;86(2):190-196. doi: 10.1134/S0006297921020073. Biochemistry (Mosc). 2021. PMID: 33832417
-
Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy.Biomed Pharmacother. 2023 Oct;166:115292. doi: 10.1016/j.biopha.2023.115292. Epub 2023 Aug 12. Biomed Pharmacother. 2023. PMID: 37579696 Review.
-
Glucarpidase following high-dose methotrexate: update on development.Expert Opin Biol Ther. 2010 Jan;10(1):105-11. doi: 10.1517/14712590903468677. Expert Opin Biol Ther. 2010. PMID: 19925307 Review.
Cited by
-
Characterization of a Stable Form of Carboxypeptidase G2 (Glucarpidase), a Potential Biobetter Variant, From Acinetobacter sp. 263903-1.Mol Biotechnol. 2021 Dec;63(12):1155-1168. doi: 10.1007/s12033-021-00370-3. Epub 2021 Jul 15. Mol Biotechnol. 2021. PMID: 34268672
-
Toward the Development of a Biosimilar Variant of Glucarpidase (Carboxypeptidase G2): Secretory Production, Optimization, and Immobilization.Mol Biotechnol. 2025 Jun 4. doi: 10.1007/s12033-025-01450-4. Online ahead of print. Mol Biotechnol. 2025. PMID: 40465023
-
Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment.PLoS One. 2018 Apr 26;13(4):e0196254. doi: 10.1371/journal.pone.0196254. eCollection 2018. PLoS One. 2018. PMID: 29698433 Free PMC article.
-
Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.Molecules. 2021 Jan 25;26(3):625. doi: 10.3390/molecules26030625. Molecules. 2021. PMID: 33504102 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources